KENVUE INC

KENVE’s launch of Neutrogena’s Cloud‑Tech™ sunscreen, the first FDA‑approved filter in 20 years, delivers high‑UVA protection in a lightweight, anti‑aging formula—boosting its beauty portfolio and market reach.

Kenvue’s lawsuit over acetaminophen’s safety in pregnancy shows how a 500‑case claim could hit a $250 million ceiling, yet the company’s dividend and strong margins keep investors confident.

Kimberly‑Clark & Kenvue’s $48.7B merger faces varied global regulatory reviews while promising cost savings, portfolio synergies and stronger supply‑chain resilience.

Pure Strategies’ “Day of Action” shows how climate‑ and nature‑focused strategies drive real business value, offering leaders insights, ROI frameworks, and cross‑sector case studies.

New drug‑free nasal spray from Zyrtec brand offers fast, multi‑hour barrier protection against pollen, dust, and pet dander—ideal for allergy sufferers seeking a medication‑free solution.

Discover why KENVEU’s new TYLENOL® with Naproxen is a first‑mover game‑changer in OTC pain relief—rapid, single‑dose, dual‑action analgesia with a three‑year exclusivity advantage.

FDA approves Kenvue’s Tylenol® with Naproxen, a fast‑acting, 12‑hour, opioid‑free OTC pain reliever combining acetaminophen and naproxen in one dose.

Explore Kenvue’s post‑spin‑off momentum: rising OTC share, tightening margins, and Cramer‑boosted confidence—plus risks and growth chances.

Executive mobility trend: Kenvue CFO Amit Banati joins Monde Le Z, revealing cross‑industry financial leadership dynamics, regulatory impacts, and strategic risks.

Howlett’s $18‑per‑share purchase of 3,000 Kenvue shares boosts her holdings to 30,000—an insider confidence signal that may reassure investors amid industry shifts.